CRSP vs CUBE · rev $37.3M vs P/E 25, rev $1.07B
Crispr Therapeutics AG (CRSP) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported CRSP revenue for 2024-12-31 was $37.3M. Net income was -$366.3M. Revenue was down 89.9% from 2023-12-31 to 2024-12-31. CRSP currently screens at market cap $5.42B.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
CRSP currently screens at market cap $5.42B. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the CRSP and CUBE stock pages for the full models.
Not investment advice.